BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

The Jackson Laboratory Partners With National Cancer Institute, University of California, Davis (UCD) to Speed New Cancer Treatments to Clinical Trials


10/29/2013 4:06:40 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

June 10, 2011 Bar Harbor, Maine—About nine out of 10 new cancer drugs successfully clear preclinical development hurdles, but then they fail in human clinical testing. The Jackson Laboratory is partnering with a component of the National Cancer Institute and The UC Davis Cancer Center to help change that outcome.

The partnership brings together The UC Davis Cancer Center, The Jackson Laboratory and the National Cancer Institute’s (NCI) Center for Advanced Preclinical Research (CAPR), all under the umbrella of NCI’s Advanced Technology Partnerships Initiative (ATPI). SAIC-Frederick facilitates translational research and development partnerships in cancer and AIDS for the ATPI as part of its longstanding operations and technical support contract with NCI.

Under the partnership, a range of genetically engineered and human transplant mouse model studies will be integrated with patient treatment clinical trial studies under a uniform and controlled testing mechanism. Data resulting from this combined approach will help identify molecules (biomarkers) that could predict conditions under which candidate drugs will be most effective. These data could be invaluable for designing clinical trials and improving treatment outcomes.

“There is an urgent need for more predictive models of human cancer for drug discovery,” said Chuck Hewett, Ph.D., Executive Vice President and COO of The Jackson Laboratory. “Unfortunately, nine out of 10 cancer drugs entering preclinical testing fail. This comes at great cost to the pharmaceutical industry and to patients. The integrated approach we have with CAPR and UC Davis targets these issues directly.”

The partnership draws on particular strengths of each organization. CAPR brings expertise in engineered mouse models, Jackson adds experience in human transplant models, and UC Davis contributes extensive knowledge of cancer drug clinical trials and laboratory resources.

The Jackson Laboratory, founded as a cancer research center in 1929, is a nonprofit biomedical research institution and National Cancer Institute-designated Cancer Center based in Bar Harbor, Maine. Its mission is to discover the genetic basis for preventing, treating and curing human diseases, and to enable research and education for the global biomedical community.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES